Financial
Latest full-year results from official filings.
FY2025 revenue $77.3m (+19.0%); operating margin -91.7%; net loss $79.0m.
Balance sheet figures not captured from release.
- Official results release · SOPHiA GENETICS · 31 Dec 2025
SOPHiA GENETICS: risk summary
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Adverse media
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving SOPHiA GENETICS found in HSH's search of the last 24 months. Jan 2026: it announced President Ross Muken would succeed co-founder Jurgi Camblong as CEO from 1 Jul 2026, with Camblong becoming Executive Chairman.
- Preliminary fourth quarter and full year 2025 financial results, initiates 2026 guidance and announces executive transition plan · SOPHiA GENETICS · 12 Jan 2026
Cyber & information governance
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator actions involving SOPHiA GENETICS found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Recalls, safety notices, regulator action and clinical safety concerns.
No recalls, safety notices or regulator actions involving SOPHiA GENETICS found in HSH's search of the last 24 months.
Contract performance
Contract delivery, go-lives, terminations and disputes.
May 2026: SOPHiA GENETICS and Synnovis (the GSTT/KCH pathology partnership) announced a partnership to offer liquid biopsy testing for lung and breast cancer under NHS England's blood test-first programme, projecting about 7,000 patients a year.
- Synnovis and SOPHiA GENETICS partner to bring blood-based cancer testing to patients across the U.K. · PR Newswire Asia · 13 May 2026